Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4837 results
Quark reports favorable results from Phase II clinical trial evaluating investigational siRNA QPI-1002
Quark Pharmaceuticals has reported data from a randomized, double-blinded, placebo-controlled multicenter Phase II clinical trial (QRK.006B; ClinicalTrials.gov identifier: NCT00802347) of QPI-1002, a synthetic chemically modified siRNA acting to reduce p53 RNA and protein levels, for the prophylaxis of delayed graft function (DGF) in deceased donor kidney transplant patients.
Drug Research > Drug Discovery & Development > News
Prometic Biosciences enters into new product development program
By PBR Staff Writer
ProMetic Life Sciences' UK subsidiary has signed an agreement with one of its existing multinational clients, a global leader in the biotherapeutics industry.
Drug Research > Drug Discovery & Development > News
National Institute of Allergy and Infectious Diseases awards SRI International Contract to study new therapies for HIV and AIDS
SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to conduct preclinical development of potential therapies for HIV infection and AIDS.
Drug Research > Drug Discovery & Development > News
Neurotrope, Mount Sinai to develop Bryostatin-1 for NPC treatment
By PBR Staff Writer
Neurotrope Bioscience has entered into a license agreement with Icahn School of Medicine at Mount Sinai to use its information and data package for the development of Bryostatin-1 to treat Niemann-Pick Type C Disease (NPC).
Drug Research > Drug Discovery & Development > News
Mezzion Pharma begins clinical development program to evaluate Udenafil in adolescents with single ventricle heart defects
Mezzion Pharma has initiated a clinical program to evaluate the use of udenafil to treat adolescents who have undergone the Fontan surgical palliation for single ventricle heart defects.
Drug Research > Drug Discovery & Development > News
ArmaGen, Shire to develop AGT-182 for treatment of hunter syndrome
ArmaGen, a privately held biotechnology company, has announced that it has entered into a worldwide licensing and collaboration agreement with Shire plc to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter syndrome.
Drug Research > Drug Discovery & Development > News
Bristol-Myers enters into immuno-oncology collaboration with Ono Pharmaceutical
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
Drug Research > Drug Discovery & Development > News
IDT Biologika - A Strategic Partner for Your Sterile Liquid Dosage Forms
| By IDT Biologika
In the highly specialized world of sterile liquid dosage forms, IDT Biologika is a contract manufacturing organization with the experience, the capability and the commitment to excellence to offer you a strategic advantage in your commercialization process. Our expertise drives our activities into higher-value pharmaceutical and biotechnology applications.
Drug Research > Drug Discovery & Development > White Papers
Cynapsus Therapeutics commences Phase II clinical trials in US
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson's disease, has announced that following communication from the United States Food and Drug Administration, Phase II clinical studies for APL-130277 will commence immediately.
Drug Research > Drug Discovery & Development > News
MYOS enters into R&D agreement with Cloud Pharmaceuticals
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research and development agreement with Cloud Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Isis Pharmaceuticals initiates Phase 2 study of ISIS-APO(a) in patients with high Lp(a)
Isis Pharmaceuticals announced the initiation of a Phase 2 study evaluating ISIS-APO(a) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
Drug Research > Drug Discovery & Development > News
Lilly, Immunocore to jointly discover and develop new cancer therapies
By PBR Staff Writer
US-based Eli Lilly and Company has entered into a co-discovery and co-development collaboration with British biotechnology firm Immunocore to research and potentially develop new T cell-based cancer therapies.
Drug Research > Drug Discovery & Development > News
BioLineRx reports results from Phase 1/2 study for celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
ChromaDex begins first human clinical study to confirm ChromaDex's NIAGEN Nicotinamide Riboside will increase NAD+
ChromaDex, an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN, the first and only commercially available form of nicotinamide riboside (NR).
Drug Research > Drug Discovery & Development > News
Roche's Phase III trial of melanoma combination therapy meets primary endpoint
By PBR Staff Writer
Roche has released positive results from the Phase III coBRIM trial of an investigational MEK inhibitor cobimetinib, used in combination with its BRAF inhibitor Zelboraf, to treat patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

IDT - Biopharmaceutical Development & Contract Manufacturing Services
IDT Biologika GmbH is an innovative, privately-held company with more than 90 years of experience in researching, developing, manufacturing and marketing of biologics. IDT operates one of Europe’s premiere integrated biological and pharmaceutical development and manufacturing facilities.... Drug Research > Drug Discovery & Development > Suppliers
PolyPeptide Group - Proprietary and Generic GMP-Grade Peptides
The PolyPeptide Group is a privately-held group of manufacturing companies that focuses on proprietary and generic GMP-grade peptides for the pharmaceutical, cosmetic and biotechnological market.... Drug Research > Drug Discovery & Development > Suppliers
Lohmann Therapy System (LTS) - Transdermal Therapeutic Systems and Oral Thin Films
LTS is the market leader in alternative drug delivery systems, in the form of transdermal therapeutic systems and oral thin films. We develop and manufacture drug delivery systems that offer patients reliable therapeutic efficacy with total comfort and convenience.... Drug Research > Drug Discovery & Development > Suppliers
Glycotope - Contract Manufacturer of Recombinant Proteins
Glycotope Biotechnology offers GMP-compliant biotechnological contract manufacturing, based on animal cell culture systems in fed-batch or perfusion fermentation technologies. We are compliant with all criteria within the European Pharmaceutical legislation, the European Pharmacopoeia, as well as EU and ICH guidelines.... Drug Research > Drug Discovery & Development > Suppliers
The Electrospinning Company - Polymer Scaffolds for 3D Cell Culture
The Electrospinning Company develops and manufactures electrospun polymer scaffolds which are incorporated into standard tissue culture plates. These provide an ideal environment for supporting the growth of cells in 3D.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

IDT Biologika - A Strategic Partner for Your Sterile Liquid Dosage Forms By IDT Biologika
In the highly specialized world of sterile liquid dosage forms, IDT Biologika is a contract manufacturing organization with the experience, the capability and the commitment to excellence to offer you a strategic advantage in your commercialization process. Our expertise drives our activities into higher-value pharmaceutical and biotechnology applications.... Drug Research > Drug Discovery & Development > White Papers Freeze Drying - Large-Scale Production for Biologics By IDT Biologika
IDT's new world-class multi-purpose high-speed filling and large-scale freeze-drying plant for human vaccines (liquid and lyophilized) is equipped to handle and respond to the complex quality and safety demands of current and future live vaccines and immunotherapeutic medicines.... Drug Research > Drug Discovery & Development > White Papers IDT Biopharmaceutical Contract Manufacturing By IDT Biologika
IDT's special expertise and capabilities include: development and aseptic filling services for parenterals in syringes, vials and ampoules; proven expertise in processing of biopharmaceutical and chemical substances; leading competence in freeze drying of narcotics; and integrated bio and pharma manufacturing site with comprehensive quality control services.... Drug Research > Drug Discovery & Development > White Papers IDT Human Vaccines Contract Manufacturing By IDT Biologika
IDT produces a wide variety of vaccines for clinical testing and is also developing new technologies for many innovative and future orientated human vaccines, for instance against tuberculosis, AIDS and malaria. Over 20 different vaccines for clinical trials in humans have been handled by IDT to date.... Drug Research > Drug Discovery & Development > White Papers Vaccines - Creating Value, Protecting Lives By IDT Biologika
IDT is a knowledgeable partner and an expert in the field of biologics contract manufacturing. IDT is focused on four business segments: animal health, vaccines, pharmaceuticals and quality control. We are a vital link in the development chain of new vaccines. Our core competency is in the contract production of viral and bacterial vaccines. We offer a comprehensive portfolio of services and solutions, from development up to large-scale production.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4837 results